Unclaimed brand
New Hope for relapsed/refractory AL Amyloidosis ASH Presentation PressRelease Corporate Presentation KOL Event to Discuss ASH 2025 NXC-201 NEXICART-2 Phase 2 Clinical Results Oral Presentation and landscape in relapsed/refractory AL Amyloidosis Hear it From the Media ASCO Post Interview: Shahzad Raza, MD (Cleveland Clinic) Memorial Sloan Kettering: Strong Results for NXC-201 at ASCO Cleveland Clinic:
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#3A5F81
Ming
58, 95, 129
209, 38, 37
55, 26, 0, 49
#FF751F
Pumpkin
255, 117, 31
23, 100, 56
0, 54, 88, 0
#012D47
Prussian Blue
1, 45, 71
202, 97, 14
99, 37, 0, 72
ImmixBio is a groundbreaking biopharmaceutical brand that was founded in 2012 by a team of visionary experts in the fields of medicine, pharmacology, and biotechnology. With a deeply personal impetus, the team at ImmixBio is dedicated to developing a revolutionary class of Tissue-Specific Therapeutics (TSTx) that aims to replace first-line therapies for a wide range of cancer indications. Recognizing the devastating impact of cancer on individuals and families, the company's objective is to provide a meaningful benefit to each patient, leaving no room for anything short of a significant impact.
ImmixBio's mission is inspired by Dr. Donald E. Senn, a brilliant biomedical scientist whose life was tragically cut short by cancer.
The brand strives to honor his memory and support all cancer patients and families worldwide in their brave fight against this disease. Contact ImmixBio at their Los Angeles headquarters to learn more about their pioneering work in the field of biopharmaceuticals
Company type
Public Company
Year founded
2012
Company size
11-50 employees
BCMA-targeted CAR-T cell therapy
AL amyloidosis drug development
Autologous cell therapy
N-GENIUS cell-therapy platform
Rare-disease immunotherapy
